Ensure that children and pets cannot access it
GLP-1 RAs and SGLT-2 inhibitors both have beneficial weight effects that should inform drug selection

may cause iron-deficiency anemia Nausea and vomiting particularly with stricturing disease/obstruction Urgency and tenesmus with rectal/colonic involvement Weight loss and malnutrition due to malabsorption, food avoidance, elevated metabolic demand Fever with active inflammation, abscess, or fistula Perianal disease fissures, fistulae, skin tags, abscesses Extraintestinal Manifestations Arthropathy peripheral or axial (enteropathic arthritis, M07.6x) Dermatologic: Erythema nodosum (L52), pyoderma gangrenosum, psoriasis (L40.5) Ocular: Uveitis/iritis (H20.01), episcleritis, scleritis Hepatobiliary: Primary sclerosing cholangitis (K73.2), fatty liver, cholelithiasis Metabolic: Osteopenia/osteoporosis (from steroid use and malabsorption), nephrolithiasis Hematologic: Anemia (iron deficiency, B12/folate deficiency, anemia of chronic disease) When a patient with Crohns disease is admitted with significant weight loss, malnutrition, or protein-calorie deficiency , query the provider to specify the degree of malnutrition (mild, moderate, severe protein-calorie malnutrition)

Product (Drug Class/Brand) Type 2 Diabetes (T2DM Byetta (exenatide) Victoza (liraglutide) Bydureon BCise (exenatide) Trulicity (dulaglutide) Adlyxin / Lyxumia (lixisenatide) Soliqua (lixisenatide/insulin glargine) FDC Xultophy / iDegLira (liraglutide / insulin degludec) FDC Ozempic (semaglutide) Rybelsus (semaglutide) Mounjaro (tirzepatide) Obesity & Weight Loss Management Saxenda (liraglutide) Wegovy (semaglutide) Zepbound (tirzepatide) Route of Administration Subcutaneous Oral Pipeline Analysis Geography North America (U.S., Canada) Latin America (Brazil, Mexico, Rest of LA) Europe (U.K., Germany, France, Italy, Spain, Rest of EU) Asia Pacific (Japan, China, India, Rest of APAC Rest of the World Company Profiles AstraZeneca plc Eli Lilly and Company Novo Nordisk A/S Sanofi S.A
Matcalf, B